PYC THERAPEUTICS LIMITED — Director's Dealing 2017

Nov 30, 2017

ASX ANNOUNCEMENT

==> picture [259 x 56] intentionally omitted <==

Appendix 3Z

PERTH, Australia, 1st December 2017 : Phylogica Limited (ASX:PYC) ( Phylogica or the Company ), submits an Appendix 3Z in relation to the retirement of Professor Paul Watt as a Director ;

As announced to ASX on 21st November 2017, Professor Watt decided not to stand for re-election as a Director of the Company at the 2017 Annual General Meeting held on 24th November 2017.

Yours faithfully

Kevin Hart

Company Secretary

ENDS

For further information, please contact:

INVESTORS MEDIA Stephanie Unwin Ben Walsh CEO WE Buchan stephanieu@phylogica.com bwalsh@buchanwe.com.au 0411 132 287 0411 520 012

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously ‘undruggable’ targets across a range of disease types. Phylogica’s platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company’s lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and is currently working with Genentech.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com Phylogica Ltd

ABN 48 098 391 961

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity PHYLOGICA LIMITED ACN 098 391 961

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	PAUL WATT
Date of last notice	26 October 2017
Date that director ceased to be director	24 November 2017

Part 1 – Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

4,044,123 Ordinary shares

• See chapter 19 for defined terms.

Appendix 3Z Page 1

11/3/2002

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances giving rise tothe relevant interestPaul Michael Watt & Maria Del PilarEnriquez-Watt ATF The BrainchildSuper FundMaria Del Pilar Enriquez-Watt	Number & class of securities10,473,074 Ordinary Shares10,000,000 Ordinary Shares10,000,000 Unlisted options expiring 30 June 2018, nilexercise price.

Part 3 – Director’s interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
No. and class of securities to whichinterest relates	N/A

• See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002